Related Experiment Video
Updated: Oct 7, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Management skin manifestation of multisystem inflammatory syndrome associated with SARS-CoV-2
Yeter Eylul Bayram1,2, Dilek Yildiz-Sevgi3, Ayse Yavuz3
1Department of Internal Medicine, Hamidiye Sisli Etfal Education and Research Hospital, Istanbul, Turkey. ytrbayram@hotmail.com.
Background:
Multisystem inflammatory syndrome (MIS), which develops after a past covid-19 infection. MIS can be described in different tissue inflammation, including the heart, lung, kidney, brain, skin, eye, and or gastrointestinal organs at the presence of COVID-19. Initially, MIS was described in Europe in children infected with SARS-CoV-2, then it was recently seen in the USA in 2020. MIS is a rare but serious disease condition associated with COVID-19 that can affect children (MIS-C) and adults (MIS-A).
Case Presentation:
A 44-year-old male who showed MIS-A in 59-day after his first covid-19 contact history. The patient presented to our emergency department with complaints of high fever, nausea, weakness, redness of the eyes, headache, and joint pain. On the second day of his hospitalization, a maculopapular skin lesion was seen in most of the skin. His fever could not be controlled even given paracetamol and broad effective antibiotics. His clinical, radiological, and laboratory findings showed that he had MIS-A. The patient was given intravenous pulse methylprednisolone and intravenous immunoglobulin (IVIG). These treatments, then, resulted in improvement of his clinical conditions, including fever and skin lesions, on the second day of the treatment. The patient was discharged in 14 days after the treatment.
Conclusion:
This report indicated that diagnosis and treatment of MIS-A could result in reducing patient morbidity and mortality.
Insights
Multisystem inflammatory syndrome in adults (MIS-A) is a rare but serious condition post-COVID-19. Early diagnosis and treatment with methylprednisolone and IVIG can significantly improve patient outcomes and reduce mortality.
Area of Science:
- Internal Medicine
- Infectious Diseases
- Pediatrics
Background:
- Multisystem inflammatory syndrome (MIS) is a rare, serious condition that can develop after COVID-19 infection.
- MIS involves inflammation in various organs, including the heart, lungs, kidneys, brain, skin, eyes, and gastrointestinal tract.
- Initially observed in children (MIS-C) in Europe, MIS has also been identified in adults (MIS-A) in the USA since 2020.
Observation:
- A 44-year-old male presented with MIS-A 59 days after COVID-19 exposure.
- Symptoms included high fever, nausea, weakness, conjunctivitis, headache, and joint pain, with a maculopapular rash developing on day two.
- Initial treatment with antipyretics and antibiotics was ineffective in controlling the fever.
Findings:
- Clinical, radiological, and laboratory findings confirmed MIS-A diagnosis.
- Treatment with intravenous pulse methylprednisolone and intravenous immunoglobulin (IVIG) led to rapid improvement.
- The patient's fever and skin lesions resolved within two days of treatment initiation.
Implications:
- This case highlights the importance of timely diagnosis and treatment for MIS-A.
- Effective management of MIS-A can significantly reduce patient morbidity and mortality.
- Prompt intervention with corticosteroids and IVIG is crucial for favorable outcomes in MIS-A patients.
More Related Videos
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:24Nephrotic Syndrome III : Nursing Management
01:14Myocarditis III: Medical Management
01:23Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
01:17Pericarditis III: Medical Management
01:22Myocarditis IV: Nursing Management